

Table 6. Adverse effects in patients receiving concurrent medication.

	Alendronate	Etidronate	Risedronate
	N(%)	N(%)	N(%)
Number of patients treated	710	181	130
Concurrent therapy			
glucocorticoids			
per os	52 (7.3)	9 (5.0)	12 (9.2)
inhaled	30 (4.2)	7 (3.8)	9 (6.9)
none	628 (88.5)	165 (91.2)	109 (83.9)
NSAIDs			
yes	288 (40.6)	81 (44.8)	48 (36.9)
no	422 (59.4)	100 (55.2)	82 (63.1)
aspirin			
yes	56 (7.9)	13 (7.2)	16 (12.3)
no	654 (92.1)	168 (92.8)	114 (87.7)
AEs	179	20	27
glucocorticoids			
per os	13 (7.3)	2 (10.0)	1 (3.7)
inhaled	12 (6.7)	1 (5.0)	5 (18.5)
none	154 (86.0)	17 (85.0)	21 (77.8)
NSAIDs			
yes	96 (53.6)	8 (40.0)	14 (51.9)
no	83 (46.4)	12 (60.0)	13 (48.1)
aspirin			
yes	17 (9.5)	1 (5.0)	5 (18.5)
no	162 (90.5)	19 (95.0)	22 (81.5)

AEs: adverse effects, GI: gastro-intestinal, NSAIDs: non-steroidal anti-inflammatory drugs. Data are presented as absolute values (percentage).